Evidence map›Paper›PMID 21072260›Full record

ArticleInternational journal of clinical and experimental medicine2010

Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art.

Arianna Malgieri, Eugenia Kantzari, Maria Patrizia Patrizi, Stefano Gambardella

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02587806 (An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells), which is not on this map. Cited by 135 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 4 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02587806 phase1 / phase2unknown statusnot on this mapstarted 2015, after this paper: background citation

An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

TypeinterventionalSponsorNovo Cellular Medicine Institute LLPRan2015 to 2017Enrolled69ConditionsMultiple Sclerosis, Relapsing-RemittingArmsAutologous Bone Marrow-Derived Mononuclear Stem Cells, Liberation therapy
3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 4 syntheses or guidelines pooled it, 292 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Osteochondral tissue engineering approaches for articular cartilage and subchondral bone regeneration.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2012
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Arianna Malgieri
Eugenia Kantzari
Maria Patrizia Patrizi
Stefano Gambardella
Fondazione Roma · ITIstituto Neurologico Mediterraneo · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) are multipotent adult stem cells present in all tissues, as part of the perivascular population. As multipotent cells, MSCs can differentiate into different tissues originating from mesoderm ranging from bone and cartilage, to cardiac muscle. MSCs are an excellent candidate for cell therapy because they are easily accessible, their isolation is straightforward, they can be bio-preserved with minimal loss of potency, and they have shown no adverse reactions to allogeneic versus autologous MSCs transplants. Therefore, MSCs are being explored to regenerate damaged tissue and treat inflammation, resulting from cardiovascular disease and myo-cardial infarction (MI), brain and spinal cord injury, stroke, diabetes, cartilage and bone injury, Crohn's disease and graft versus host disease (GvHD). Most of the application and clinical trials involve MSCs from bone marrow (BMMSCs). Transplantation of MSCs from bone marrow is considered safe and has been widely tested in clinical trials of cardiovascular, neurological, and immunological disease with encouraging results. There are examples of MSCs utilization in the repair of kidney, muscle and lung. The cells were also found to promote angiogenesis, and were used in chronic skin wound treatment. Recent studies involve also mesenchymal stem cell transplant from umbilical cord (UCMSCt). One of these demonstrate that UCMSCt may improve symptoms and biochemical values in patients with severe refractory systemic lupus erythematosus (SLE), and therefore this source of MSCs need deeper studies and require more attention. However, also if there are 79 registered clinical trial sites for evaluating MSC therapy throughout the world, it is still a long way to go before using these cells as a routinely applied therapy in clinics.

Indexed as

cell therapymesenchymal stem cellsregenerative medicineUmbilical cord bloodumbilical cord blood banking

Identifiers

PMID21072260
PMCPMC2971538
OpenAlexW1515496124

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.